Eplontersen (branded Wainua in the US, Wainzua in the EU) is an FDA-approved antisense oligonucleotide from Ionis Pharmaceuticals (IONS) and partner AstraZeneca for treating hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). It generated $212M in global 2025 sales, with Ionis receiving $49M in royalties. The drug's pivotal Phase 3 CARDIO-TTRansform trial for the much larger ATTR cardiomyopathy (heart) indication failed its primary endpoint on July 9, 2026, causing IONS stock to drop ~20%. A prespecified monotherapy subgroup showed a nominally significant benefit, but the overall miss was a major setback that boosts competitor drugs from Alnylam (Amvuttra) and BridgeBio (Attruby). The approved hATTR-PN business continues, but the largest value-driving opportunity is now off the table.
Wainua (eplontersen) is an FDA-approved antisense oligonucleotide for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), co-developed and commercialized by AstraZeneca and Ionis Pharmaceuticals. It generated $212M in global sales in 2025. However, on July 9, 2026, the pivotal CARDIO-TTRansform Phase 3 trial in the much larger ATTR cardiomyopathy (ATTR-CM) indication failed its primary endpoint of reducing cardiovascular mortality and recurrent CV events. This is a significant setback because ATTR-CM represents a blockbuster market already dominated by Pfizer's tafamidis (~$4B) and contested by BridgeBio's acoramidis and Alnylam's vutrisiran. For AstraZeneca ($587B cap), the impact is manageable; for Ionis (~$5B cap), it is a more severe blow to its growth narrative.
Semaglutide is the blockbuster GLP-1 drug behind Novo Nordisk's Ozempic, Wegovy, and Rybelsus — a class generating tens of billions in annual sales. Dr. Reddy's Laboratories (NYSE: RDY) was the first generic to enter the Canadian market (April 2026) and launched its own semaglutide injection and oral tablet (branded Obeda) in India. However, on July 9, 2026, Dr. Reddy's suspended production after detecting an API impurity, slashing its FY27 supply target from 12M to 6-7M pens and wiping ~$678M from its market cap. Semaglutide is a very large commercial opportunity for generic manufacturers as patents expire globally, but near-term execution risk at Dr. Reddy's is significant.
CardiolRx is a pharmaceutical-grade oral cannabidiol (CBD) solution being developed by Cardiol Therapeutics (CRDL) for inflammatory heart conditions. Its lead indication is recurrent pericarditis, where a Phase II study showed a 71% recurrence-free rate and symptom improvement, leading to an ongoing pivotal Phase III MAVERIC trial. Enrollment is at ~75% with topline data expected H2 2026. The drug also showed positive Phase II results in acute myocarditis (ARCHER trial). The company is a micro-cap (~$115M market cap) with CardiolRx as its sole late-stage asset, making the upcoming MAVERIC readout a binary event. Analyst consensus is Strong Buy with a mean target of ~$7.20, but significant equity dilution and the high-risk Phase III binary create a wide range of potential outcomes for the stock.
DA-1726 is MetaVia Inc.'s lead drug candidate — a GLP-1/glucagon dual agonist (a type of obesity treatment) currently in Phase 1 trials. Early data showed 9.1% mean weight loss at 48mg over 8 weeks, which is competitive with established drugs but was from a small, early-stage cohort. The company just completed dose titration on Part 3 (higher doses up to 64mg), with topline data due Q4 2026. MetaVia has a tiny ~$8M market cap, heavy dilution via an ATM offering, and faces overwhelming competition from Novo Nordisk, Eli Lilly, and Boehringer Ingelheim/Zealand Pharma whose survodutide just showed 16.6% weight loss in Phase 3. The stock is a binary bet on the Phase 1 readout — success could yield enormous percentage returns given the micro-cap, but the odds are long.
AXS-05 (Auvelity) is Axsome Therapeutics' lead commercial drug — an oral, fixed-dose combination of dextromethorphan and bupropion. Originally FDA-approved for major depressive disorder in August 2022, it became the first oral NMDA receptor antagonist and first new mechanism of action for MDD in over six decades. On April 30, 2026, the FDA significantly expanded the label to include agitation associated with Alzheimer's disease dementia — the first non-antipsychotic ever approved for that indication. Auvelity generated $507.1 million in U.S. net product sales in FY2025 (74% YoY growth), and management projects peak annual sales of at least $8 billion across both indications. The commercial launch for Alzheimer's agitation began in June 2026. The stock has rallied strongly (~155% from its 52-week low) on the approval and raised guidance, but as an already-approved drug with no new binary regulatory catalyst pending near-term, the next 12 months are about commercial execution rather than a binary event.
ImmuneSelect is Virax Biolabs' commercially available research-use-only (RUO) T-cell immune profiling product line — not a drug. Launched in April 2024, it includes ELISpot assay plates, peptide pools, and antibodies sold to academic and pharma researchers for immune monitoring. On July 9, 2026, Virax signed an exclusive multi-country supply agreement with Fosun Diagnostics covering six Southeast Asian markets, driving the stock up 100%+ in a single session. However, Virax remains a development-stage company with only $12K in FY2026 revenue, a $5M annual net loss, an accumulated deficit exceeding $24M, and a recent 1-for-25 reverse stock split to maintain Nasdaq listing. The product faces entrenched competition from established ELISpot/FluoroSpot suppliers, and the Fosun deal's financial terms (volume-based tiers with performance-linked exclusivity) have no disclosed minimums, making near-term revenue impact uncertain.
XPro1595 (pegipanermin) is INmune Bio's lead drug candidate — a first-in-class selective soluble TNF inhibitor targeting neuroinflammation in early Alzheimer's disease. The Phase 2 MINDFuL trial (n=207) missed its primary cognitive endpoint in the overall population but showed encouraging trends in a biomarker-enriched subgroup (amyloid-positive with 2+ inflammation markers). The FDA granted Fast Track designation (May 2026) and aligned on a Phase 2b/3 registrational pathway (Feb 2026). The stock trades at ~$1.72 (~$43M market cap) near its 52-week low, reflecting the mixed Phase 2 results, cash runway concerns (~$21.4M through Q1 2027), and the capital-intensive Phase 3 path ahead. The amyloid-targeting competition (Leqembi, Kisunla) is already approved, but XPro1595's novel anti-inflammatory mechanism could differentiate it if the registrational program succeeds.
Bel-sar (belzupacap sarotalocan / AU-011) is Aura Biosciences' lead and only late-stage asset — a first-in-class virus-like drug conjugate (VDC) being developed as a vision-sparing first-line therapy for early choroidal melanoma, a rare eye cancer. Phase 2 results showed 80% tumor control and 90% vision preservation, which supported the design of the Phase 3 CoMpass trial under a Special Protocol Assessment (SPA) with the FDA. Enrollment of 108 patients completed in June 2026, with topline data expected in H2 2027 — the stock's defining binary event. The company also has early-stage data in bladder cancer (NMIBC) showing promising complete response rates. A $299M equity offering in May 2026 funded the company through H2 2028 but massively diluted existing shareholders. The stock trades at ~$7 with a consensus analyst target of $18.80, reflecting strong confidence in the Phase 3 data but with significant execution risk still ahead.
Nebokitug is Chemomab's only clinical-stage asset — a first-in-class antibody targeting CCL24 for fibro-inflammatory diseases. Phase 2 data in PSC (a rare liver disease with NO approved therapies) was positive and published in a top journal. The FDA has aligned on a streamlined single-trial Phase 3 path. However, the Phase 3 has not launched due to funding constraints. On July 8, 2026, Chemomab announced a merger with Scipher Medicine (all-stock; Chemomab holders get ~32% of the combined entity plus CVRs), bringing $30M in financing and a new AI-guided Phase 2 RA program. The stock had already surged ~80% into the deal. The drug's value proposition is strong — a large unmet-need market with regulatory tailwinds — but execution risk on Phase 3 financing, dilution from the merger, and the very early-stage RA program keep the read mixed near-term.
SER-155 is Seres Therapeutics' lead live biotherapeutic candidate — an oral bacterial consortia designed to prevent deadly bloodstream infections in stem cell transplant patients. Phase 1b data showed a striking 77% relative risk reduction in bloodstream infections, earning FDA Breakthrough Therapy Designation. The company finalized a Phase 2 protocol with the FDA but paused the study in February 2026 to conserve cash after laying off 30% of staff. A fresh catalyst came July 8, 2026, with positive early data in a second indication (irEC, a nasty side effect of cancer immunotherapy), where 80% of patients responded without immunosuppressives. The stock sold off sharply on the news. SER-155 is clinically compelling but Seres is a cash-constrained micro-cap trading at ~$79M market cap with runway only into Q1 2027, making the stock a binary bet on the company's ability to secure a partnership or funding.
PM647 is Prime Medicine's preclinical Prime Editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder affecting ~100,000 people in the US that can cause both lung (emphysema) and liver disease. On July 8, 2026, Prime Medicine won a binding arbitration against Beam Therapeutics, confirming PM647 is within Prime Medicine's licensed field and clearing a major legal overhang. With ~$227M in cash (Q3 2025) funding operations into 2027, the company plans to file an IND/CTA for PM647 in Q3 2026. Preclinical data in humanized mouse models showed restoration of M-AAT protein into the clinically healthy range. However, competition is fierce: Beam Therapeutics already has Phase 1/2 data for BEAM-302, and CRISPR Therapeutics, Regeneron/Tessera, and AIRNA are advancing rival AATD programs.
Qelbree (viloxazine/SPN-812) is Supernus Pharmaceuticals' lead growth product — a once-daily non-stimulant ADHD medication that was the first new non-stimulant ADHD drug approved in a decade. Launched in 2021 for children and expanded to adults in 2023, Qelbree has delivered strong commercial momentum: net sales hit $241M in 2024 (+72% YoY), exceeded $300M in 2025 (+26%), and reached $77.9M in Q1 2026 (+20% YoY). It competes mainly against Strattera (generic atomoxetine) in the non-stimulant segment and against a large field of stimulants. The key risk is a Paragraph IV patent challenge filed in May 2025 by generic manufacturers targeting Qelbree's six Orange Book patents (expiring 2029-2035). Supernus has diversified somewhat with three other growth products (GOCOVRI, ZURZUVAE, ONAPGO) but Qelbree remains the largest single revenue driver at roughly 37% of total company revenue.
TRUTAKNA (atacicept-vymj) is Vera Therapeutics' first approved product — a dual BAFF/APRIL inhibitor for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The FDA granted accelerated approval on July 7, 2026, following positive Phase 3 ORIGIN 3 data showing 46% proteinuria reduction. As the first approved therapy targeting the root immunological cause of IgAN, it competes in a growing market projected to reach ~$730M in 2024 and expand at ~30% CAGR. Vera had ~$715M in cash as of Dec 2025 and can access up to $500M via an Oxford debt facility ($75M drawable on this approval). Analyst consensus is Strong Buy with a mean price target of $78 (~80% upside from ~$43), though the approval event produced only a modest +6.8% stock move, suggesting market expectations were already baked in. Key risks include a crowded competitive landscape (Novartis, Otsuka, Travere, Calliditas), pricing/reimbursement pressures, and the need to confirm eGFR benefits for full approval in Q3 2026.
ATH434 is an oral iron-chaperone drug from Alterity Therapeutics (ATHE) targeting Multiple System Atrophy (MSA), a rare, fatal neurodegenerative disease with NO approved disease-modifying treatments. Phase 2 data showed a 48% slowing of disease progression at the 50mg dose (p=0.02) and was published at AAN 2025. The drug has FDA Fast Track and Orphan Drug designations. In July 2026, the FDA officially confirmed the registrational pathway for a Phase 3 pivotal trial. Competition includes Lundbeck's amlenetug (Phase 3, anti-alpha-synuclein antibody). Alterity has ~A$49M cash (~9 quarters runway at current burn) but will likely need to raise capital to fund the pivotal trial.
TTI-101 is a first-in-class, oral STAT3 inhibitor being developed by Tvardi Therapeutics (TVRD, ~$3/share, ~$19M market cap) for hepatocellular carcinoma (liver cancer). The drug showed promising Phase 1 data (60% clinical benefit rate, 20% confirmed partial responses in HCC) but suffered a major setback when its Phase 2 IPF trial failed in October 2025, sending the stock down ~84%. All eyes are now on the Phase 1b/2 REVERT LIVER CANCER topline data expected in 2H 2026 — the company's last standing clinical catalyst. With only ~$25M cash runnning through Q4 2026 and a $200M shelf registration creating dilution overhang, this is a high-risk binary. The recent positive TTI-109 (next-gen prodrug) Phase 1 data provides some pipeline optionality but does not solve the near-term funding gap.
Allocetra is Enlivex's lead pipeline asset — an off-the-shelf, macrophage-reprogramming cell therapy targeting a huge unmet need in knee osteoarthritis (a $314B longevity market with no approved disease-modifying drugs). Phase 2a data showed statistically significant pain reduction (up to 72% in patients aged 60+) and functional improvement sustained at 6 months. The Phase 2b trial was cleared by the FDA and Danish regulators in early 2026, with first patients expected mid-2026 and topline data ~12 months out. However, ENLV is a micro-cap ($127M equity) with a history of heavy dilution (252M shares pre-reverse split, 1:15 reverse split announced July 2026) and a highly unusual treasury strategy holding ~$1.14B in RAIN prediction-market tokens — making the stock hard to value as a pure biotech. Past Phase 2 success does not guarantee Phase 2b success, and the long timeline means shareholders face years of dilution risk.
GX-03 is Turn Therapeutics' lead investigational drug — a first-in-class topical cream targeting IL-36 and IL-31 cytokines for moderate-to-severe atopic dermatitis (eczema). The company is currently running an adaptive Phase 2 trial. Interim data on the first 50 subjects (June 2026) showed strong efficacy: 92.6% of patients achieved at least a 50% reduction in eczema severity (EASI-50) at week 4, with 70.4% achieving EASI-75 and 44.4% EASI-90. No treatment-related serious adverse events were reported. The trial has been expanded to ~120-135 patients across the full severity spectrum, with topline results expected in Q4 2026 alongside a planned FDA Type-B meeting. Turn Therapeutics went public via direct listing in late 2025, has $11.2M cash plus a $25M loan facility, and analyst consensus is strongly bullish (6 buy/strong-buy, 1 hold).
SAB-142 is SAB Biotherapeutics' only clinical-stage asset — a fully human, re-dosable anti-thymocyte globulin (hATG) being developed as a disease-modifying therapy for autoimmune type 1 diabetes. Phase 1 data showed C-peptide preservation and a clean safety profile. The registrational Phase 2b SAFEGUARD trial is actively enrolling, with topline data expected in 2H 2027. The company has $217.6M in cash (runway through 2028), strong institutional backing (RA Capital, Balyasny, Adage Capital, Millennium, BlackRock all added in Q1 2026), and a consensus Strong Buy rating from 11 analysts with a mean price target of $11.18 (vs ~$3.92). The recent FDA accelerated approval of Sanofi's Tzield (teplizumab) for Stage 3 T1D in June 2026 partially de-risks both the regulatory pathway and the commercial thesis for SAB-142.
VCN-01 is an oncolytic adenovirus (zabilugene almadenorepvec) being developed by Theriva Biologics (TOVX, ~$10M market cap) primarily for metastatic pancreatic ductal adenocarcinoma (PDAC). A 112-patient Phase 2b trial (VIRAGE) met its primary endpoints in 2025, showing a meaningful survival benefit (median OS 10.8 vs 8.6 months, HR ~0.44 for death risk reduction) when combined with standard chemo. The FDA and EMA both aligned on a Phase 3 design in early 2026. However, the company has only ~$14M cash (runway into Q1 2027) and cut 32% of its workforce to conserve capital. The pivotal Phase 3 is unfunded, making partnership or dilutive financing a critical near-term need. A major competitive overhang is Revolution Medicines' daraxonrasib, which nearly doubled survival in a 500-patient Phase 3 trial for KRAS-mutant PDAC (~90% of cases). VCN-01 targets a different mechanism (tumor stroma, all-comers regardless of mutation) and could be complementary, but daraxonrasib's data has reshaped the pancreatic cancer treatment landscape.
-
Botaretigene sparoparvovec (bota-vec) is a late-stage AAV5-based gene therapy for X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease causing blindness with no approved treatments. MeiraGTx reacquired full rights from Johnson & Johnson in April 2026 for $25M upfront after the Phase 3 LUMEOS trial missed its primary endpoint but showed positive secondary visual-function results. The company plans immediate global regulatory filings (US, EU, Japan) with manufacturing already validated and a potential 2027 commercial launch. Bota-vec is a key value driver for MGTX alongside other pipeline programs, supported by recent $400M Oberland Capital financing. The mixed Phase 3 data creates regulatory uncertainty but the drug benefits from FDA Fast Track and Orphan Drug designations.
Explore drug → -
AAV2-hAQP1 is MeiraGTx's lead gene therapy program for radiation-induced xerostomia (chronic dry mouth), a condition affecting over 170,000 patients in the US with no FDA-approved therapies. Phase 1 data showed durable 3-year safety and efficacy from a single administration. The drug has received both FDA Breakthrough Therapy and RMAT designations. The Phase 2 AQUAx2 pivotal trial readout (late 2026/early 2027) is the key catalyst, supported by a recent $400M Oberland Capital financing that includes $50M tied to positive Phase 2 data. With a strong analyst consensus (13 Buy-equivalent ratings, 1 Hold, mean PT $28.25) and de-risked regulatory path, the drug represents a potentially first-in-class treatment for a large unmet need.
Explore drug →
Mitapivat is an oral pyruvate kinase (PK) activator developed by Agios Pharmaceuticals (AGIO) — already approved and commercialized in two rare blood-disease indications (PK deficiency as PYRUKYND, 2022; thalassemia as AQVESME, Dec 2025). Q1 2026 revenue more than doubled to $20.7M with 242 thalassemia prescriptions written. The defining near-term catalyst is the November 1, 2026 PDUFA date for accelerated approval in sickle cell disease — a vastly larger market opportunity. The RISE UP Phase 3 data were mixed: strong hemoglobin and transfusion-burden results, but the pain-crisis primary endpoint missed. Approval would unlock peak sales estimated at $1B+. The stock trades at ~$37-42 with 12 buy/strongBuy ratings, 4 holds, 0 sells, and a mean analyst target around $40.75. A boxed warning for liver injury and a REMS program apply to the thalassemia label.
Urcosimod (formerly OK-101) is OKYO Pharma's sole pipeline asset — an investigational eye-drop for neuropathic corneal pain (NCP), a chronic condition with no FDA-approved therapies. A small but positive Phase 2a trial (18 patients) showed 75% of patients on 0.05% urcosimod achieved >80% pain reduction at 12 weeks. The FDA has granted Fast Track designation and endorsed a 120-patient Phase 2b/3 design. OKYO is a micro-cap (~$70-86M market cap) with strong analyst support (8 Buy-equivalent ratings, mean price target $9 vs ~$1.61 current). However, the company has limited cash runway and will almost certainly need dilutive financing to complete the pivotal program, making this a high-risk/high-reward single-asset story.
Neflamapimod is an oral p38α inhibitor being developed by CervoMed (CRVO, ~$28M market cap) primarily for Dementia with Lewy Bodies (DLB). The drug has a complex clinical history: it originally failed its Phase 2b (RewinD-LB) topline in Dec 2024 on the primary endpoint, but a new capsule formulation with better bioavailability produced statistically significant positive results in the extension phase (Mar 2025), supported by biomarker and MRI data. FDA aligned on a Phase 3 registration path in Nov 2025. However, the company has undergone heavy dilutive financing (raising ~$20.5M in June 2026 via a PIPE and a registered direct offering) and explicitly states Phase 3 initiation is contingent on a strategic partnership. The stock trades near its 52-week low with a consensus of 12 buy ratings and 1 hold, and a mean analyst price target of $19.50 (436% implied upside), though these targets predate the latest dilution.
PEMGARDA (pemivibart) is Invivyd's only commercialized product — a monoclonal antibody authorized under FDA Emergency Use Authorization since March 2024 for preventing COVID-19 in immunocompromised people who don't respond well to vaccines. It generated ~$53.4M in revenue in FY2025 and ~$13.7M in Q1 2026 (+22% YoY). However, on July 6, 2026, Invivyd announced the FDA issued a Notice of EUA Termination effective June 29, 2027, following HHS's broader COVID-19 EUA declaration wind-down. Invivyd says it is in dialogue with FDA and plans to pursue a Biologics License Application (BLA) for full approval. The EUA termination creates a ~12-month clock on PEMGARDA's revenue. The company's future increasingly depends on its next-generation candidate VYD2311 (Phase 3 data due Q3 2026), which has an FDA-aligned rapid BLA pathway.
Piclidenoson is Can-Fite BioPharma's lead anti-inflammatory drug candidate, a first-in-class oral A3 adenosine receptor agonist in pivotal Phase 3 testing for moderate-to-severe plaque psoriasis. It has demonstrated a compelling safety profile (comparable to placebo, superior to leading oral drug Otezla) across 2,000+ patients, though prior data showed modestly lower efficacy than Otezla on standard skin-clearance measures. The current pivotal Phase 3 trial just hit its enrollment milestone on July 6, 2026, triggering an interim analysis whose results (expected Q4 2026–Q1 2027) represent the stock's next major binary catalyst. The oral psoriasis market is growing crowded (Otezla, Sotyktu, newly-approved Icotyde from J&J), raising commercial risk. Can-Fite is pre-revenue with severe cash constraints ($6.45M as of mid-2025) and frequent dilutive fundraising, though it has out-licensing partners in Canada, Europe, and veterinary applications that provide non-dilutive upside.
IBC101 is a pre-clinical-stage bivalent CD19xCD22 CAR-T cell therapy targeting relapsed/refractory B-cell malignancies, acquired by Liminatus Pharma (LIMN) via a $320M all-stock merger with InnocsAI that closed July 2, 2026. It has IND approval from South Korean regulators for a Phase 1/2a study in DLBCL that hasn't started enrollment. The host company is a distressed micro-cap ($~6-7M market cap) facing Nasdaq delisting and potentially extreme dilution (~29x) from the merger consideration structure. The CAR-T field is dominated by approved products from Novartis, Gilead, BMS, and J&J, and multiple competing CD19/CD22 dual-targeting programs are in development by better-capitalized players. For a non-medical investor, IBC101 is a very early pipeline story at a company that may not survive to see the drug reach patients.
Dupixent (dupilumab) is a blockbuster injectable biologic co-developed and co-commercialized by Regeneron (REGN) and Sanofi (SNY). First approved in 2017 for atopic dermatitis, it is now FDA-approved for 9 indications spanning dermatology, respiratory, and gastroenterology — including the landmark COPD approval in September 2024. Global net sales reached ~$17.8 billion in 2025 (up 26% YoY), and it is widely considered one of the best-selling drugs in the world. For Regeneron, Dupixent is the primary growth engine, with the company recording collaboration revenue of $2.06 billion from Sanofi in H1 2025 (up 18% YoY). The bull case centers on continued label expansion into large markets like COPD and chronic urticaria, with peak sales estimates exceeding $22 billion. The bear case centers on imminent patent expiration (earliest patents 2027-2031), potential biosimilar competition from Amgen and others, safety litigation around a potential T-cell lymphoma signal, and competitive pressure from next-gen IL-13 inhibitors like Eli Lilly's lebrikizumab.
Deucrictibant is Pharvaris' oral bradykinin B2 receptor antagonist for hereditary angioedema (HAE), developed in two formulations: an immediate-release capsule (PHVS416) for on-demand attack treatment and an extended-release tablet (PHVS719) for daily prophylaxis. The IR capsule produced strong Phase 3 RAPIDe-3 data (median symptom relief in 1.28 hours, p<0.0001) and the FDA accepted its NDA on July 6, 2026 with a PDUFA date of April 23, 2027. The XR tablet's Phase 3 CHAPTER-3 prophylaxis study completed enrollment and topline data is expected Q3 2026. While the clinical profile is compelling, deucrictibant faces a significant competitive disadvantage: KalVista's sebetralstat (EKTERLY) was already FDA-approved in July 2025 as the first oral on-demand HAE therapy and has a head start on commercial build-out. Analyst consensus is Strong Buy (9 Buy, 2 Hold) with a mean price target of $46.34, implying ~60% upside from ~$33.86.